Compare Ascendis Pharma A/S (ASND) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs American Water Works Company Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while American Water Works Company Inc trades at $130.7 (market cap $25.52B). The key difference: American Water Works Company Inc is the larger of the two by market cap, and American Water Works Company Inc pays a 2.74% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AWK | |
|---|---|---|
Market Cap | $17.74B | $25.52B |
Sector | Health | Utilities |
52-Week High | $277.18 | $147.00 |
52-Week Low | $163.32 | $121.13 |
Enterprise Value | $18.11B | $41.08B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
American Water Works (AWK) trades at $130.69, up 0.11% with a neutral technical outlook. The stock shows strong fundamentals with consistent revenue growth from $3.8B in 2022 to $5.1B in 2025, maintaining profit margins above 21%. Recent developments include infrastructure investments and regulatory approvals, while analyst consensus leans slightly bullish with a $137 price target.
AWK presents a stable investment opportunity with predictable utility earnings and dividend income. Key risks include regulatory rate approvals and capital expenditure requirements. The stock offers moderate upside potential with balanced analyst sentiment supporting long-term growth in essential water services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
